DarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers

Rhea-AI Summary

DarioHealth (Nasdaq: DRIO) has announced a strategic partnership with a leading national benefit administrator to provide its cardiometabolic solution, including a GLP-1 support program and AI-driven digital health suite to employers. The partnership, which began contributing to revenue in January 2025, addresses rising healthcare costs associated with metabolic conditions.

The collaboration targets the GLP-1 market, projected to reach $100 billion by 2030, and the cardiometabolic disease market, expected to exceed $1.2 trillion by 2033. Dario's comprehensive approach addresses the challenge of GLP-1 medication discontinuation through personalized coaching, AI-driven monitoring, and behavior change strategies.

This partnership marks Dario's first national benefit administrator collaboration, enabling faster employer onboarding and immediate impact on B2B2C recurring revenues for 2025. The agreement serves as a foundational entry into a priority growth segment and provides a reference model for expansion across other national administrators and payer channels.

Strategic partnership expands Dario's employer footprint and has already started contributing to recurring revenues in Q1 of 2025

NEW YORK, April 17, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new strategic partnership with a leading benefit administrator to deliver its comprehensive cardiometabolic solution including a GLP-1 support program and full AI-driven digital health suite to employers, with initial clients already implemented and contributing to revenue since January 2025. This marks Dario's first national benefit administrator partnership and represents a strategic step toward broader adoption across benefit administration channels.

The benefit administrator selected Dario's integrated platform to address rising healthcare costs associated with metabolic conditions including diabetes, pre-diabetes, hypertension, and weight management. The partnership specifically targets the growing demand for effective GLP-1 medication support as employers seek solutions that maximize the clinical and economic benefits of these breakthrough therapies while ensuring sustainable outcomes for members.

This collaboration expands Dario's footprint in multiple fast-growing healthcare segments, including the GLP-1 market projected to grow to $100 billion by 2030 and the broader cardiometabolic disease market projected to surpass $1.2 trillion by 2033.¹ Research into the field indicates that without proper behavioral support, 50-75% of patients discontinue GLP-1 medications within one year. ² Dario's comprehensive approach addresses this challenge through a complete lifecycle management solution—supporting members from medication initiation through long-term weight maintenance with personalized coaching, AI-driven monitoring, and sustainable behavior change strategies.

"We are thrilled to partner with one of the fastest growing benefits administrators in the country to support their goals of delivering market-leading health benefits that help reduce costs associated with healthcare," said Steven Nelson, Chief Commercial Officer at Dario. "This strategic partnership unlocks new distribution channels that align with payer-driven models such as Third Party Administrators (TPAs) and benefits platforms, as well as expanding in the employer market. Due to the shorter sales cycle, we were able to begin onboarding employers quickly after the January launch, with the ability to add employers off-cycle as well, maximizing the availability of Dario's solutions to the employer population and creating an immediate impact on our Business-to-Business-to-Consumer (B2B2C) recurring revenues for 2025. This partnership highlights our solution to the growing challenge clients face as healthcare costs continue to increase, particularly for chronic conditions and GLP-1 medications. We view this partnership as a foundational entry into a priority growth segment."

We believe that this agreement further validates Dario's position as a leading provider of integrated digital health solutions addressing the complex challenges of chronic condition management, particularly as employers and health plans seek effective strategies to manage the rising costs associated with GLP-1 medications while ensuring optimal health outcomes. We believe it also provides a proven reference model we can replicate across other national administrators and payer channels, reinforcing our B2B2C strategy.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. 

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses that the GLP-1 market is projected to grow to $100 billion by 2030 and that the broader cardiometabolic disease market projected to surpass $1.2 trillion by 2033, its belief that the collaboration is a foundational entry into a priority growth segment and its belief that the collaboration provides a proven reference model it can replicate across other national administrators and payer channels . Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact

Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280

DarioHealth Investor Relations Contact

Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922

¹ I. GLP-1 Market: https://www.goldmansachs.com/insights/articles/anti-obesity-drug-market;  II. Cardiometabolic Disease Market: https://straitsresearch.com/report/cardiometabolic-disease-market

² https://news.northwestern.edu/stories/2024/11/why-do-50-75-of-people-stop-taking-glp-1-drugs-within-a-year/

 

 

Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/dariohealth-collaborates-with-leading-national-benefit-plan-administrator-to-offer-cardiometabolic-solution-including-a-glp-1-support-program-to-employers-302431446.html

SOURCE DarioHealth Corp.

FAQ

What is the projected market size for GLP-1 medications by 2030 according to DarioHealth's announcement?

According to the announcement, the GLP-1 market is projected to grow to $100 billion by 2030.

How does DarioHealth (DRIO) address GLP-1 medication discontinuation rates?

DRIO provides a complete lifecycle management solution with personalized coaching, AI-driven monitoring, and sustainable behavior change strategies to support members from medication initiation through long-term weight maintenance.

When did DarioHealth's new benefit administrator partnership begin generating revenue?

The partnership began contributing to recurring revenues in January 2025.

What is the projected size of the cardiometabolic disease market by 2033 mentioned in DRIO's announcement?

The cardiometabolic disease market is projected to surpass $1.2 trillion by 2033.

What percentage of patients discontinue GLP-1 medications within one year without proper support?

According to the announcement, 50-75% of patients discontinue GLP-1 medications within one year without proper behavioral support.